Arrowhead Pharmaceuticals, Inc. (ARWR) |
23.78 -0.14 (-0.59%) 04-23 16:00 |
Open: | 23.95 |
High: | 24.68 |
Low: | 23.67 |
Volume: | 803,217 |
Market Cap: | 2,946(M) |
PE Ratio: | -8.58 |
Exchange: | NASDAQ Global Select |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 29.93 |
Resistance 1: | 26.81 |
Pivot price: | 24.60 |
Support 1: | 21.75 |
Support 2: | 18.10 |
52w High: | 42.48 |
52w Low: | 20.67 |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
EPS | -285350016.000 |
Book Value | 0.000 |
PEG Ratio | -1.16 |
Gross Profit | -130.972 |
Profit Margin (%) | -163.32 |
Operating Margin (%) | -3.00 |
Return on Assets (ttm) | 845.3 |
Return on Equity (ttm) | -24.7 |
Wed, 24 Apr 2024
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney ... - Business Wire
Tue, 23 Apr 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Up 7.5% - MarketBeat
Fri, 19 Apr 2024
First Week of December 20th Options Trading For Arrowhead Pharmaceuticals (ARWR) - Nasdaq
Tue, 16 Apr 2024
Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 6.6 ... - Yahoo Finance
Mon, 01 Apr 2024
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is largely controlled by institutional shareholders who own 63% of the company - Simply Wall St
Fri, 08 Mar 2024
Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation ... - Simply Wall St
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |